Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Leads Biolabs Approved to Start China/US Trials of Bispecific for Multiple Myeloma

publication date: Jul 31, 2023

Nanjing Leads Biolabs was approved to start China and US trials of LBL-034, an anti-GPRC5D/CD3 bispecific antibody aimed at treating relapsed/refractory multiple myeloma. The first-in-human, dose-escalation and expansion clinical study will enroll patients with rrMM who have failed prior therapies. The G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D) is a C-type 7-channel transmembrane receptor protein that has low expression in normal human tissues but is overexpressed in multiple myeloma. So far, no GPRC5D-targeting antibody has been approved to launch anywhere in the world. More details.....

Share this with colleagues:  



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital